Patent Assignment Details
NOTE:Results display only for issued patents and published applications.
For pending or abandoned applications please consult USPTO staff.
|
| Reel/Frame: | 057528/0064 | |
| Pages: | 5 |
| | Recorded: | 09/08/2021 | | |
| Attorney Dkt #: | 102538.0080PRO,P2,US,3,4 |
| Conveyance: | CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). |
|
|
Total properties:
3
|
|
|
|
Patent #:
|
|
Issue Dt:
|
06/27/2023
|
Application #:
|
16883263
|
Filing Dt:
|
05/26/2020
|
|
Publication #:
|
|
Pub Dt:
|
09/16/2021
| | | | |
|
Title:
|
REPLICATION-DEFECTIVE ADENOVIRUSES COMPRISING NUCLEIC ACIDS ENCODING SARS-COV-2 S GLYCOPROTEIN AND MODIFIED N PROTEIN COMPRISING AN ENDOSOMAL TARGETING SEQUENCE
|
|
|
|
|
Patent #:
|
|
Issue Dt:
|
01/02/2024
|
Application #:
|
17198164
|
Filing Dt:
|
03/10/2021
|
|
Publication #:
|
|
Pub Dt:
|
10/26/2023
| | | | |
|
Title:
|
METHOD OF INDUCING IMMUNITY AGAINST SARS-COV-2 USING SPIKE (S) AND NUCLEOCAPSID (N)-ETSD IMMUNOGENS DELIVERED BY A REPLICATION-DEFECTIVE ADENOVIRUS
|
|
|
|
|
Patent #:
|
NONE
|
Issue Dt:
|
|
Application #:
|
17405393
|
Filing Dt:
|
08/18/2021
|
|
Publication #:
|
|
Pub Dt:
|
01/20/2022
| | | | |
|
Title:
|
ANTI COVID-19 THERAPIES USING NUCLEOCAPSID AND SPIKE PROTEINS
|
|
|
Assignee
|
|
|
|
|
| 9920 JEFFERSON BLVD. |
| CULVER CITY, CALIFORNIA 90232 |
|
|
Correspondence name and address
|
| |
UMBERG ZIPSER LLP
|
| |
1920 MAIN STREET, SUITE 750
|
| |
IRVINE, CA 92614
|
Search Results as of:
06/22/2024 05:28 PM
If you have any comments or questions concerning the data displayed,
contact
PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified:
August 25, 2017 v.2.6
|
